Testosterone Therapy Done Right: Benefits, Dosing, Injection Options, and Bloodwork

For men with symptoms and confirmed testosterone deficiency, testosterone replacement therapy can improve important parts of daily life. Sexual desire, body composition, and certain consequences of deficiency may respond to treatment. The opportunity is meaningful when the diagnosis and treatment plan fit.

Good TRT begins with a clear goal: relieve symptoms and restore appropriate hormone levels while watching for unwanted effects. The largest dose or highest laboratory result is not the measure of success.

Haptic offers a Colorado testosterone cypionate program with a labs-ordered option. The care team determines eligibility and the tests needed for each patient. This guide explains the clinical questions behind treatment, including injection options and a practical distinction between an Optimizing phase and an Optimized phase.

The benefits, with the evidence in view

Sexual desire and activity. In the Testosterone Trials, 790 symptomatic men aged 65 or older with low testosterone received testosterone gel or placebo for a year. Treatment improved sexual activity, desire, and erectile function. The findings support a real benefit in an appropriate population, although ED can have other causes requiring separate treatment. Snyder and colleagues, 2016.

Mood and well-being. The same trials found modest improvements in mood and depressive symptoms. They did not establish testosterone as a general treatment for depression or a reliable energy enhancer. The primary vitality outcome did not significantly improve. Testosterone Trials.

Lean mass and body composition. Research in hypogonadal men has found increased lean mass and reduced fat mass during replacement. In one longer-term gel study, these changes were maintained, but muscle strength did not significantly increase. The study lacked a placebo group. These results should not be turned into guaranteed strength, athletic performance, or weight-loss promises. Wang and colleagues.

Bone density. Testosterone can improve bone density in men with deficiency. That does not establish fracture prevention. In a large TRAVERSE substudy, clinical fractures occurred more often in the testosterone group than the placebo group. Men with osteoporosis still need a specific bone-health assessment and treatment plan. Snyder and colleagues, 2024.

Correction of anemia in some men. A randomized TRAVERSE analysis found that testosterone was more effective than placebo at correcting anemia in men with hypogonadism. Anemia still requires an evaluation of its cause. Increasing red blood cells can be helpful when levels are low and harmful when they become excessive. Pencina and colleagues.

Benefits in one domain should not be stretched into claims about every domain. Clearer thinking, greater confidence, better sleep, and longer life are not outcomes to promise from TRT. At follow-up, focus on the symptoms that prompted treatment and what has actually changed.

Confirm the diagnosis before choosing a dose

Symptoms alone are not enough. Low testosterone should be confirmed with reliable testing, usually two separate morning measurements, interpreted with the clinical history. Free testosterone can help when total testosterone is borderline or binding proteins make it difficult to interpret. LH and FSH help distinguish testicular from pituitary or hypothalamic causes.

The Endocrine Society guideline emphasizes consistent low results, compatible symptoms, and evaluation of the underlying cause. Fatigue or reduced libido can also reflect other medical or psychological issues.

Urologist and researcher Mohit Khera, MD, discusses this broader evaluation in his interview on The Peter Attia Drive. An expert interview can help frame questions; it does not replace the individual's assessment.

Proper dosing means matching exposure to response

For intramuscular testosterone cypionate or enanthate, the Endocrine Society's guideline describes 75 to 100 mg weekly as one commonly used regimen. This is educational context, not a starting prescription for every reader. Product labeling, the patient's situation, and clinical judgment govern the actual plan. Full clinical guideline.

A clinician adjusts treatment using symptoms, appropriately timed testosterone measurements, and safety findings. A dose that is appropriate for one man may produce excessive exposure or little benefit in another. Persistent symptoms despite appropriate levels are a reason to reconsider their cause, not automatically keep increasing testosterone.

Milligrams describe the amount of drug. Milliliters describe the volume injected. The relationship depends on the vial concentration, so changes in product or concentration require careful instruction.

Weekly versus multiple injections per week

Some patients do well with one weekly injection. Others discuss dividing the same weekly amount into smaller, more frequent injections to try to reduce fluctuations between doses. This is a pharmacokinetic rationale, not proof that twice-weekly treatment gives everyone better outcomes.

For illustration only, a prescribed total of 100 mg per week could be divided into two 50 mg doses if the clinician directs it. Taking 100 mg twice weekly would double the exposure. Never change frequency without confirming the total dose and instructions.

A study comparing 100 mg weekly with 200 mg every two weeks found less hematocrit elevation above 54% in the weekly group. It did not compare once-weekly with twice-weekly dosing. We should not use it to claim that more frequent dosing is always safer. Comparative regimen study.

The best schedule is one that achieves appropriate levels, helps symptoms, and can be followed consistently.

Deep intramuscular versus subcutaneous injections

Intramuscular, or IM, injection places medication into muscle. Subcutaneous, or SubQ, injection places it into the fatty tissue beneath the skin. Neither is better simply because it is deeper or uses a shorter needle.

Testosterone cypionate labeling specifies intramuscular use. Subcutaneous cypionate is an off-label route that some clinicians use. Xyosted is a different product, a testosterone enanthate autoinjector approved specifically for subcutaneous administration. Its approval does not extend to every testosterone vial. See the cypionate label and Xyosted label.

A small study of 11 transgender patients receiving weekly SubQ cypionate found relatively stable testosterone concentrations between injections. That supports feasibility but does not prove superior long-term outcomes for hypogonadal men. Subcutaneous testosterone study.

Route selection depends on the specific product, clinician judgment, comfort, local reactions, and correct technique. Haptic's public program page does not establish that SubQ cypionate is offered. Ask the care team which route is prescribed. Get product-specific training on the injection site, equipment, and sharps disposal rather than changing technique from an online demonstration.

What a good TRT bloodwork evaluation includes

A useful panel answers specific questions. It is not necessary to order every hormone at every visit.

The AUA testosterone guideline explains targeted testing. Lipids, A1c or glucose, thyroid tests, kidney or liver tests, and iron studies may be appropriate for particular symptoms or risk factors, rather than a universal TRT requirement.

Bloodwork also has limits. Blood pressure, sleep-apnea symptoms, medication use, and fertility goals belong in the assessment. Semen analysis may be needed when fertility is relevant; a normal testosterone result does not establish normal sperm production.

Haptic can arrange bloodwork through its labs-ordered program option. Confirm the ordered tests and follow-up schedule with the care team rather than assuming every item above is included in a fixed package.

The Optimizing phase: quarterly review and bloodwork

Think of the early phase as finding a regimen that works safely. Quarterly bloodwork and clinical review can provide a useful structure while symptoms, dose, and safety measurements are being assessed. This is a care framework, not a rule to wait three months when something needs earlier attention.

Guidance recommends checking testosterone and hematocrit after initiation, commonly within three to six months. For cypionate or enanthate, mid-interval testosterone testing is one guideline approach. A consistent relationship between the blood draw and injection makes comparisons more useful. Endotext monitoring recommendations.

Dose changes, new symptoms, or abnormal findings can justify earlier checks. Track symptom response alongside laboratory values so a normal result does not obscure a treatment that is not helping.

The Optimized phase: annual bloodwork for selected stable patients

Once the dose, symptoms, and safety results are stable, monitoring can become less frequent. Annual bloodwork may be appropriate for selected patients. The AUA recommends testosterone measurement every six to twelve months, so yearly testing is the longer end of that range. AUA guideline.

“Optimized” should mean a stable, reviewed plan. New symptoms, elevated hematocrit, medication changes, or a dose adjustment can bring testing forward. Haptic's clinician sets the actual interval based on the individual situation.

Supplemental medications should solve a specific problem

TRT should not automatically come with an estrogen blocker or fertility medication. The decision needs a diagnosis, symptoms, relevant testing, and a clear purpose.

For men with infertility and low testosterone, specialists may consider hCG, selective estrogen receptor modulators such as clomiphene, or selected aromatase inhibitors. Clomiphene use in men is off-label. These approaches are not interchangeable with routine TRT and do not guarantee fertility. The AUA/ASRM infertility guideline advises against exogenous testosterone for men interested in current or future fertility.

An isolated estradiol result should not automatically trigger anastrozole. Estradiol contributes to normal physiology, and unnecessary suppression can be harmful. Finkelstein and colleagues demonstrated distinct roles for testosterone and estradiol in body composition and sexual function. Breast symptoms and the overall treatment exposure need assessment. Nutritional supplements should similarly address an actual deficiency or clinical indication. These examples do not establish that Haptic offers the additional medications.

Side effects and safety deserve active follow-up

Potential adverse effects include acne, fluid retention, injection-site reactions, reduced sperm production, and increased hematocrit. Discuss sleep-apnea symptoms and prostate-related concerns before and during treatment. Cypionate prescribing information.

A hematocrit above 54% calls for clinician-directed intervention, including evaluation of contributing causes and adjustment or interruption of treatment. Repeated blood donation is not a substitute for managing the regimen. Endotext monitoring guidance.

FDA's 2025 labeling changes removed boxed-warning language about increased cardiovascular events while adding or strengthening blood pressure warnings. This does not make TRT risk-free or prove that every regimen has the same safety profile. FDA's announcement.

Research outlook: what may come next

Much of the useful progress in TRT concerns better patient selection, delivery, and monitoring. The evidence presented here does not establish a reliable near-term launch date for a new therapy that replaces those fundamentals.

Research-only hormone or peptide products should remain outside a routine care plan. We will distinguish investigational findings from actual approval and verified availability as evidence develops. For now, the strongest foundation is an accurate diagnosis, an appropriate prescription, and follow-up that connects benefits with safety.

Educational information, not an individual dosing or injection plan. A licensed clinician determines diagnosis, treatment, and monitoring.